Urinary system disorder
MONDO:0002118A disease involving the renal system.
Also known as: disease of renal system, disease or disorder of renal system, disease, urinary tract, disease, urologic, disease, urological, diseases, urinary tract, diseases, urologic, diseases, urological
4758 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could a vitamin d pill help kids with kidney disease avoid dialysis?
Disease control TerminatedThis phase 3 trial compares two oral vitamin D therapies—Hectorol (doxercalciferol) and Rocaltrol (calcitriol)—in children aged 5 to 18 with chronic kidney disease stages 3 or 4 who have high parathyroid hormone levels but are not yet on dialysis. The main goal is to see if Hecto…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a common blood pressure drug shrink kidney tumors?
Disease control TerminatedThis pilot study tested whether propranolol, a beta-blocker, could shrink or stabilize kidney angiomyolipomas in people with tuberous sclerosis. Only 2 participants were enrolled before the trial was terminated, so the results are very limited. The goal was to find a less invasiv…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Personalized interferon therapy aims to tame kidney disease without weakening defenses
Disease control TerminatedThis phase 2 trial investigates whether a personalized course of peginterferon alfa-2a can control membranous nephropathy, an autoimmune kidney disease. The treatment targets the Th17 inflammatory pathway, which is linked to a higher risk of relapse. Participants receive injectio…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control TerminatedThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Kidney drug trial for infants and toddlers halted early
Disease control TerminatedThis study tested a liquid medicine called paricalcitol in children aged 0 to 9 years with severe kidney failure who are on dialysis. The goal was to see if it safely lowers high parathyroid hormone levels, a common complication. The trial was stopped early after enrolling only 2…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo tackles brain tumors in melanoma and kidney cancer patients
Disease control TerminatedThis study tested a combination of two drugs, pembrolizumab and lenvatinib, in 18 adults with melanoma or kidney cancer that had spread to the brain. Participants had already received anti-PD-1/PD-L1 therapy. The goal was to see if the drug combo could shrink or eliminate brain t…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug aims to keep acid in check for rare kidney disorder
Disease control TerminatedThis study tested a medicine called ADV7103 in children and adults with distal renal tubular acidosis (dRTA), a rare kidney condition that causes too much acid in the blood. The goal was to see if ADV7103 could prevent dangerous acid buildup better than a placebo. Only 3 people e…
Phase: PHASE3 • Sponsor: Advicenne Pharma • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so f…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New sling offers hope for women with stress incontinence
Disease control TerminatedThis study followed 598 women who received the Altis Single Incision Sling, a minimally invasive mesh device, to treat stress urinary incontinence. Researchers tracked how well the sling worked and monitored safety over 12 and 36 months after implantation. The goal was to see if …
Sponsor: Coloplast A/S • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Bladder cancer radiation trial halted early
Disease control TerminatedThis study looked at whether giving radiation therapy after bladder removal surgery could help prevent cancer from coming back in the pelvis. It included 14 people with advanced bladder cancer. The trial was stopped early, so we don't have clear answers on whether the radiation h…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Bladder cancer combo therapy trial cut short – what we know
Disease control TerminatedThis phase 2 trial tested whether adding the immunotherapy avelumab to standard chemotherapy (gemcitabine-cisplatin) helps people with advanced bladder cancer that has spread. The study planned to enroll 65 patients but was terminated early. Researchers measured tumor shrinkage a…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Mistletoe vs. chemo: bladder cancer trial halted early
Disease control TerminatedThis study aimed to see if a mistletoe extract placed directly into the bladder could delay cancer return better than standard chemotherapy in 174 people with early-stage bladder cancer. The trial was stopped early, so results are limited. The approach focuses on controlling the …
Phase: PHASE3 • Sponsor: Abnoba Gmbh • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
Disease control TerminatedThis phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental cancer pill targets genetic weakness in Hard-to-Treat tumors
Disease control TerminatedThis study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cocktail of cancer drugs tested in desperate cases
Disease control TerminatedThis early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Tiny study tests diuretics for dialysis patients – terminated early
Disease control TerminatedThis pilot study tested two diuretics (furosemide and chlorthalidone) in people on dialysis who still had some kidney function. The goal was to see if these water pills could help preserve remaining kidney function, increase urine output, and reduce weight gain between dialysis s…
Phase: PHASE4 • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Less invasive kidney stone surgery may match standard approach
Disease control TerminatedThis study compared two surgical methods for removing kidney stones between 2 and 4 centimeters: flexible ureteroscopy (a less invasive scope through the urinary tract) and percutaneous nephrolithotomy (a small incision in the back). The goal was to see if the less invasive optio…
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New kidney stone tool tested – but study stopped early
Disease control TerminatedThis study tested a new device called ClearPetra, which uses suction to remove kidney stone fragments during surgery, against the usual approach. Only 3 adults with kidney stones were enrolled before the study was stopped. The goal was to see if the device could clear stones bett…
Phase: NA • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Promising vasculitis drug trial halted early
Disease control TerminatedThis study compared two drugs, obinutuzumab and rituximab, for treating a rare autoimmune disease that inflames blood vessels (ANCA-associated vasculitis). The goal was to see if obinutuzumab could help more patients achieve remission and clear disease markers. However, the trial…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental triple therapy for advanced cancers shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Hydroxychloroquine trial for rare vasculitis halted early
Disease control TerminatedThis study tested whether hydroxychloroquine, a drug used for lupus and arthritis, could help control ANCA vasculitis—a group of autoimmune diseases that cause blood vessel inflammation. Adults with mild disease activity were randomly assigned to receive hydroxychloroquine or a p…
Phase: PHASE4 • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Bladder cancer drug trial halted early after enrolling just 4 patients
Disease control TerminatedThis small study tested whether giving the drug sacituzumab govitecan before surgery could help people with a rare type of muscle-invasive bladder cancer. The drug targets cancer cells and delivers chemotherapy directly to them. Only 4 people took part before the study was stoppe…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental cancer drug OMX-0407 trial halted early
Disease control TerminatedThis early-phase trial tested OMX-0407, a new drug that blocks certain enzymes, in 68 adults with advanced solid tumors that had stopped responding to other treatments. The study aimed to find a safe dose and check if the drug could shrink tumors. However, the trial was terminate…
Phase: PHASE1, PHASE2 • Sponsor: iOmx Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Bladder cancer radiation trial halted early – only 2 patients enrolled
Disease control TerminatedThis study tested a new type of radiation therapy that adapts daily to the patient's anatomy, combined with chemotherapy, for muscle-invasive bladder cancer. The goal was to see if this approach could lower severe bowel and bladder side effects compared to standard radiation. How…
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Oxygen chamber treatment for diabetic kidneys falls short
Disease control TerminatedThis study looked at whether hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) could help people with diabetic kidney disease. The goal was to see if it could improve kidney function and reduce protein in the urine. However, the study was stopped early an…
Phase: NA • Sponsor: Assaf-Harofeh Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Kidney-Liver drug trial halted early – what happened?
Disease control TerminatedThis small Phase 2 study tested two doses of vonafexor, an oral drug, in 10 people with mild-to-moderate chronic kidney disease and suspected MASH (a type of fatty liver disease). The goal was to see if vonafexor could improve kidney function. However, the trial was terminated ea…
Phase: PHASE2 • Sponsor: Enyo Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental combo for tough cancers shows early promise, but trial halted
Disease control TerminatedThis early-phase study tested a combination of two drugs—atezolizumab (an immunotherapy) and epacadostat (an oral drug that helps the immune system attack cancer)—in 29 patients with advanced lung or bladder cancer that had already been treated with chemotherapy. The main goal wa…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental cancer drug AUR106 tested in humans for first time
Disease control TerminatedThis early-stage trial tested an experimental drug called AUR106 in 21 adults with advanced solid tumors (lung, stomach, bladder, kidney, colon, or esophageal cancer) that had come back or spread. The main goals were to check safety, find the right dose, and see how the drug move…
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New cancer drug AUR109 tested in three tumor types – trial halted early
Disease control TerminatedThis phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was t…
Phase: PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New blood thinner tested for cancer Patients' clots – study halted early
Disease control TerminatedThis phase 3 trial tested a new drug, abelacimab, against a standard blood thinner (dalteparin) to prevent dangerous blood clots from returning in people with gastrointestinal or genitourinary cancers. The study enrolled 417 adults with advanced cancer and a recent clot. It was t…
Phase: PHASE3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Pazopanib dose hunt in frail seniors halted early
Disease control TerminatedThis phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…
Phase: PHASE1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental immune cell therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…
Phase: PHASE1 • Sponsor: Instil Bio • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can cutting carbs and a diabetes drug help kidneys?
Disease control TerminatedThis small pilot study tested whether a low-carb diet (50-100 grams of carbs per day) combined with the diabetes drug dapagliflozin could improve blood sugar control in people with chronic kidney disease and prediabetes or type 2 diabetes. Four participants were split into two gr…
Phase: NA • Sponsor: Department of Nephrology Clinic Ottakring Vienna • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
PNH drug iptacopan tested in Real-World setting – but study cut short
Disease control TerminatedThis study looked at how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) when used in everyday medical practice in Russia. Only 6 adults took part, and the study was terminated early. Researchers measured whether patients' hemoglobin levels…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental cancer drug BAT8007 tested in early trial – but study halted
Disease control TerminatedThis early-phase trial tested a new drug called BAT8007 in 93 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target a protein called Nectin-4 on cancer cells and deliver a chemotherapy agent directly to them. The main…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Blockchain app aims to cut hospital visits for dialysis patients
Disease control TerminatedThis trial tested a smartphone app (SKI App) that uses blockchain and AI to help dialysis patients track their health data and get personalized care tips. The goal was to see if the app could reduce emergency room visits and hospital stays compared to a basic health app. The stud…
Phase: NA • Sponsor: China Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Kidney shield drug fails early test in heart surgery patients
Disease control TerminatedThis study tested a single dose of TIN816, given as an IV infusion, to see if it could prevent acute kidney injury in adults after cardiac surgery. The trial enrolled 102 patients aged 45 and older who were at risk for kidney damage. However, the study was terminated early, so we…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New shockwave machine aims to blast kidney stones away
Disease control TerminatedThis study tested a new device called the Enhanced Lithotripsy System (ELS) that uses shockwaves from outside the body to break kidney stones into tiny pieces. The goal was to see if it could safely clear stones or leave only very small fragments (less than 3 mm) after up to two …
Phase: NA • Sponsor: Avvio Medical • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New vitamin d pill aims to tame parathyroid glands in dialysis patients
Disease control TerminatedThis phase 2 study tested a weekly extended-release capsule of calcifediol (CTAP101) in 44 adults with chronic kidney disease on hemodialysis who also had vitamin D insufficiency and secondary hyperparathyroidism. The goal was to see if the drug could raise vitamin D levels and l…
Phase: PHASE2 • Sponsor: OPKO Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Hormone blocker added to chemo for bladder cancer: early study halted
Disease control TerminatedThis early study tested adding a testosterone-lowering drug (degarelix) to standard chemotherapy for people with muscle-invasive bladder cancer that has testosterone receptors. Only 2 people enrolled before the study was stopped. The goal was to see if the combination could elimi…
Phase: PHASE1 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug OMS721 tested for rare kidney conditions
Disease control TerminatedThis study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental bladder cancer drug shows promise but trial halted early
Disease control TerminatedThis study tested an experimental drug called enfortumab vedotin, alone or with other cancer drugs, in people with advanced bladder or urinary tract cancer. The goal was to see if the drug could shrink tumors and control the disease. The trial included 348 participants but was te…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Pfizer tests new drug combo for advanced cancers – but study ends early
Disease control TerminatedThis early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo tested for advanced kidney cancer shows promise but study halted early
Disease control TerminatedThis study tested a combination of two drugs, sitravatinib and nivolumab, in people with advanced kidney cancer that had spread and worsened after prior treatment. The goal was to see if the combination could shrink tumors or slow the disease. The study was stopped early after en…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
Immune cell therapy tested for tough childhood cancers
Disease control TerminatedThis early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Blood test aims to balance infection and rejection risks in kidney transplants
Disease control TerminatedThis study looked at whether a blood test called ImmuKnow can help doctors better manage anti-rejection drugs in kidney transplant patients. The goal was to reduce infections while still preventing organ rejection. Only 4 patients were enrolled before the study was stopped early,…
Phase: PHASE4 • Sponsor: CAMC Health System • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Aspirin study for kidney patients halted early – did the risks outweigh the benefits?
Disease control TerminatedThis study looked at whether taking a daily low-dose aspirin could help people with chronic kidney disease avoid their first heart attack or stroke. Over 4,600 participants were randomly assigned to take aspirin or receive usual care. The trial was stopped early, and the final re…
Phase: PHASE3 • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo for kidney cancer shows promise but trial halted early
Disease control TerminatedThis phase 3 study tested whether adding atezolizumab (an immunotherapy) to cabozantinib (a targeted therapy) helps people with advanced kidney cancer whose disease worsened after prior immunotherapy. The trial enrolled 522 participants but was terminated early, so the full benef…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can a simple urine test prevent kidney failure in sepsis?
Disease control TerminatedThis study tested whether using a urine biomarker test (NephroCheck) to guide treatment could reduce kidney injury, dialysis, or death in sepsis patients. The trial planned to enroll many participants but was stopped early after only 19 people joined. The idea was to catch kidney…
Phase: NA • Sponsor: BioMérieux • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Kidney cancer drug combo trial stopped early – what happened?
Disease control TerminatedThis study tested two drugs (toripalimab and lenvatinib) given before and after kidney cancer surgery in people with different stages of kidney cancer. The goal was to see if the treatment could shrink or eliminate the tumor before surgery and keep cancer from coming back after. …
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New cancer drug PRO1160 tested in advanced cancers – trial ends early
Disease control TerminatedThis study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental kidney cancer drug trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Quit smoking before surgery to cut complications, study finds
Disease control TerminatedThis study looked at whether a structured smoking cessation program starting four weeks before surgery could reduce complications in smokers undergoing intermediate to high-risk operations. Researchers planned to enroll 251 adult smokers scheduled for surgeries like abdominal, th…
Phase: NA • Sponsor: Luzerner Kantonsspital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cancer drug shows early promise, but trial cut short
Disease control TerminatedThis early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Hiprex trial for recurrent UTIs halted early – little data to go on
Disease control TerminatedThis study aimed to see if Hiprex (methenamine hippurate) could reduce recurrent urinary tract infections in women aged 50 to 85. Participants took Hiprex daily for a year, and researchers counted infections and antibiotic use. However, the trial was terminated early with only 14…
Phase: PHASE4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Early trial of experimental cancer combo halted after 21 patients
Disease control TerminatedThis early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New cancer drug QEQ278 tested in Early-Stage trial
Disease control TerminatedThis early-stage trial tested a new drug, QEQ278, in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cancer drug tested in rare tumors, but trial stopped early
Disease control TerminatedThis phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Kidney disease drug trial halted early after only 6 patients
Disease control TerminatedThis early-stage study tested a new drug called VB119 in 6 adults with primary membranous nephropathy, a kidney disease. The main goal was to check safety and how the body handles the drug, not to cure the disease. The study was terminated early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Tenet Medicines • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Early dialysis after heart surgery: study halted, but clues remain
Disease control TerminatedThis study looked at whether starting dialysis early helps people with acute kidney injury after heart surgery. It included 44 adults who developed moderate kidney damage within a week of surgery. The trial was stopped early, so results are limited, but the goal was to see if ear…
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Timing of dialysis in septic shock: early vs. delayed – study halted early
Disease control TerminatedThis study looked at 500 adults with septic shock and severe acute kidney injury to see if starting dialysis early (within 12 hours) or waiting (48-60 hours) affected survival at 90 days. The trial was terminated early, so the results are not conclusive. The goal was to find the …
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Lupus kidney drug for teens shows promise, but trial cut short
Disease control TerminatedThis study tested a drug called voclosporin in teenagers with lupus nephritis, a kidney disease caused by lupus. The goal was to see if it could improve kidney function better than a placebo. Only 9 teens took part before the study was stopped early, so we don't have clear answer…
Phase: PHASE3 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Lupus kidney drug tested in kids – but study stopped early
Disease control TerminatedThis study looked at the long-term safety of the drug voclosporin in adolescents and children with lupus nephritis, a kidney disease caused by lupus. Participants took voclosporin capsules twice daily along with standard medications. The trial was terminated early and only enroll…
Phase: PHASE3 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Gene therapy trial for advanced kidney cancer halted early
Disease control TerminatedThis study tested a one-time gene therapy called Temferon in 10 people with advanced kidney cancer that had worsened after standard treatments. The goal was to see if it was safe and could activate the immune system against tumors. The trial was terminated early, so results are l…
Phase: PHASE1, PHASE2 • Sponsor: Genenta Science • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Kidney transplant breakthrough? drug combo aims to reduce lifelong pills
Disease control TerminatedThis study tested a drug called siplizumab combined with donor bone marrow cells to help kidney transplant patients potentially stop taking anti-rejection drugs long-term. Only 4 people took part before the study was ended early. The goal was to find the best dose to safely allow…
Phase: PHASE2 • Sponsor: ITB-Med LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental vaccine combo for rare adrenal cancers shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or…
Phase: PHASE1, PHASE2 • Sponsor: Enterome • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental CAR t therapy targets lupus and related diseases – but trial ends early
Disease control TerminatedThis early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the imm…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a probiotic pill stop UTIs from coming back?
Disease control TerminatedThis study tested a daily probiotic supplement containing Lactobacillus plantarum, cranberry, and vitamin C to see if it could prevent recurrent urinary tract infections (UTIs) in women. The trial planned to enroll 106 women with a history of frequent UTIs, but it was terminated …
Phase: NA • Sponsor: AB Biotics, SA • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy for tough bladder cancer cases shows early promise
Disease control TerminatedThis study tested a combination of two drugs, selinexor and pembrolizumab, in people with advanced bladder cancer who either couldn't take the standard chemo drug cisplatin or whose cancer got worse after cisplatin. The goal was to find the best dose and see if the combo could sh…
Phase: PHASE1, PHASE2 • Sponsor: Mamta Parikh • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Cancer drug combo trial for kids halted early
Disease control TerminatedThis early-stage study tested a combination of two drugs, niraparib and dostarlimab, in children and teens (ages 6 months to 17 years) with solid tumors that had come back or were not responding to treatment. The goal was to find a safe dose and see if the drugs could shrink tumo…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental drug ravulizumab tested for kidney inflammation
Disease control TerminatedThis Phase 2 study tested the drug ravulizumab (Ultomiris) in 123 adults with lupus nephritis or IgA nephropathy, two conditions that cause kidney inflammation. Participants received either ravulizumab or a placebo alongside standard care. The study aimed to see if the drug could…
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental liver drug shows early promise but trial cut short
Disease control TerminatedThis early study tested a drug called VS-01 in 15 adults with acute-on-chronic liver failure (a sudden worsening of liver function) and fluid buildup in the belly. Participants received either VS-01 plus standard care or standard care alone. The trial was terminated early, so we …
Phase: PHASE2 • Sponsor: Genfit • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control TerminatedThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Kidney drug trial halted: did it help or harm?
Disease control TerminatedThis study tested a drug called sodium zirconium cyclosilicate (SZC) to see if it could slow down chronic kidney disease (CKD) in people who also have high potassium levels. Over 1,100 adults with moderate-to-severe CKD took SZC or a placebo alongside their regular blood pressure…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Radioactive 'Smart Bomb' for tumours tested in early trial
Disease control TerminatedThis early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Bladder cancer drug combo trial halted early
Disease control TerminatedThis study tested a combination of two drugs, futibatinib and pembrolizumab, in 43 people with advanced or metastatic bladder cancer who could not receive standard chemotherapy. The goal was to see if the combo could shrink tumors and to check its safety. The trial was terminated…
Phase: PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for kidney patients with Hard-to-Match immune systems
Disease control TerminatedThis study tested two drugs, daratumumab and belatacept, in 5 highly sensitized dialysis patients waiting for a kidney transplant. The goal was to safely reduce the antibodies that make it very hard to find a compatible donor kidney. The trial was stopped early, but it aimed to h…
Phase: PHASE2 • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Kidney disease drug combo shows promise in small trial
Disease control TerminatedThis study looked at whether adding cyclosporine to rituximab is more effective than rituximab alone for treating idiopathic membranous nephropathy, a kidney disease that causes protein leakage. Only 12 adults with severe proteinuria took part before the study ended early. The go…
Phase: PHASE3 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Blood filter during heart bypass may prevent organ damage, but trial stopped early
Disease control TerminatedThis study tested a device called Efferon LPS that filters blood during heart surgery when a heart-lung machine is used. The goal was to see if it could prevent multiple organ failure, especially kidney damage. Only 14 people took part before the study was stopped, so the results…
Phase: NA • Sponsor: Efferon JSC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can two diabetes drugs save kidneys after cancer surgery?
Disease control TerminatedThis study looked at whether two drugs, finerenone and empagliflozin, can slow kidney function decline in people at high risk for chronic kidney disease after having a kidney removed for cancer. Ten participants took one or both drugs or no drug for a year. The trial was terminat…
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Needle-Free blood vessel connection for dialysis patients tested
Disease control TerminatedThis study tested a device called everlinQ endoAVF that creates a connection between an artery and a vein using a thin tube (catheter) instead of open surgery. The goal was to make it easier for people with chronic kidney disease to get dialysis. The trial enrolled 100 adults who…
Phase: NA • Sponsor: C. R. Bard • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Kidney disease drug trial halted midway
Disease control TerminatedThis study tested a drug called OMS721 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. The trial was stopped early, so results are limited.
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Kidney cancer drug combo trial halted early – what we know
Disease control TerminatedThis early-stage trial tested a combination of two immunotherapy drugs, aldesleukin (IL-2) and pembrolizumab, in 6 people with advanced kidney cancer that had spread. The goal was to find the safest dose and see if the combination could shrink tumors. The study was terminated ear…
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Lupus kidney drug trial halted midway
Disease control TerminatedThis study tested a drug called zetomipzomib for people with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if the drug could improve kidney function better than a placebo over 52 weeks. The trial was terminated early, so results are limited. Partic…
Phase: PHASE2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Immunotherapy combo tested for rare kidney cancer, but trial stopped early
Disease control TerminatedThis phase II trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 people with a rare and aggressive kidney cancer called renal medullary carcinoma. The goal was to see if the drugs could shrink tumors or slow cancer growth. However, the study was terminated earl…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Cancer combo trial halted early – what went wrong?
Disease control TerminatedThis phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Cancer drug combo trial halted early – what we know
Disease control TerminatedThis trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Quick test could spare kids from strong antibiotics for UTIs
Disease control TerminatedThis study tested whether a rapid lab test (looking for integrons in urine) could help doctors choose a narrow-spectrum antibiotic instead of a broad-spectrum one for children with fever and a urinary tract infection. The goal was to see if this approach works as well as standard…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New bladder cancer drug delivered directly into bladder shows early promise
Disease control TerminatedThis early-phase trial tested enfortumab vedotin, a drug placed directly into the bladder via a catheter, in 37 people with a type of bladder cancer that did not respond to standard BCG therapy. The main goals were to check safety and side effects, and to see if the drug could he…
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Kidney cancer drug combo tested before surgery – study halted early
Disease control TerminatedThis study looked at whether giving the immunotherapy drug pembrolizumab (with or without axitinib) before surgery could help control advanced kidney cancer. Only 6 people took part before the study was stopped early. The goal was to see if the treatment boosted immune cells in t…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…
Phase: PHASE1 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a simple drug make donated kidneys start working faster?
Disease control TerminatedThis study tested whether the drug heme arginate can help transplanted kidneys work right away, instead of being slow to start. It included 47 adults receiving a kidney from a deceased donor. Participants got either the drug or a salt water solution at transplant and 24 hours lat…
Phase: PHASE3 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New pill shows promise for Hard-to-Treat kidney cancer
Disease control TerminatedThis study tested an oral drug called NKT2152 in people with advanced clear cell renal cell carcinoma that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The trial was terminated early, but the data may still help guid…
Phase: PHASE1, PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Kidney cancer combo trial halted early – what we know
Disease control TerminatedThis study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had worsened after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was …
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Bladder cancer drug combo study halted early
Disease control TerminatedThis study looked at whether adding an immunotherapy drug (pembrolizumab) to a targeted therapy (pemigatinib) works better than the targeted therapy alone or standard care for people with advanced bladder cancer that has a specific gene change (FGFR3). The study was stopped early…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental cancer drug LY3405105 fails to advance in early trial
Disease control TerminatedThis early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Bladder cancer drug combo trial halted early – what we know
Disease control TerminatedThis phase 2 study tested several drug combinations (retifanlimab, epacadostat, INCAGN02385, INCAGN02390) given before bladder removal surgery in 30 patients with muscle-invasive bladder cancer who could not take the standard chemo drug cisplatin. The trial was terminated early, …
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy shows promise for tough bladder cancer
Disease control TerminatedThis study tested whether adding the immunotherapy drug avelumab to standard radiation could help treat muscle-invasive bladder cancer in patients who cannot receive the usual chemotherapy. Fourteen participants received the combination therapy. The goal was to see if the cancer …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-phase study tested an experimental drug called ABBV-303, alone or with another drug (budigalimab), in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was termin…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control TerminatedThis study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…
Phase: PHASE2 • Sponsor: Tempus AI • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
BCX9930 safety checked in PNH patients who benefited from treatment
Disease control TerminatedThis study looked at the long-term safety of BCX9930, an oral medication, for people with paroxysmal nocturnal hemoglobinuria (PNH) who had already benefited from the drug in a previous study. It included 28 participants and aimed to monitor side effects. The study was terminated…
Phase: PHASE2 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Cancer cocktail trial halted early – what went wrong?
Disease control TerminatedThis study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated …
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated, …
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo aims to stop immune attack after kidney transplant
Disease control TerminatedThis study tested whether a drug called imlifidase, given with other medications, could prevent the immune system from attacking a new kidney in highly sensitized patients. These patients have a very high risk of rejecting a donated kidney. The study was stopped early after only …
Phase: PHASE2 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental combo therapy for advanced cancer shows promise but trial ends early
Disease control TerminatedThis study tested a new treatment for people with non-small cell lung cancer or kidney cancer that had spread to up to six spots in the body. The treatment combined a special type of radiation therapy (PULSAR) with immunotherapy drugs (pembrolizumab or nivolumab), with or without…
Phase: PHASE2 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug trial ends early
Disease control TerminatedThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Actym Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Kidney disease drug trial halted midway: what happened?
Disease control TerminatedThis study tested a drug called ALXN2050 in people with kidney inflammation caused by lupus (lupus nephritis) or IgA nephropathy. The goal was to see if it could reduce protein in the urine, a sign of kidney damage. About 100 adults were planned to take the drug or a placebo alon…
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo aims to save bladders in cancer fight
Disease control TerminatedThis trial tested whether adding gemcitabine to standard cisplatin and radiation therapy could help control muscle-invasive bladder cancer while preserving the bladder. About 69 patients were enrolled to compare the combination against standard treatment. The study was terminated…
Phase: NA • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Bladder cancer drug combo trial stalls early
Disease control TerminatedThis small phase II study tested whether combining the chemotherapy drug docetaxel with the targeted therapy lapatinib could help patients with advanced bladder cancer that had already been treated with platinum-based chemo. Only 15 people enrolled before the study was terminated…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug targets genetic weakness in tough cancers
Disease control TerminatedThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Heart-Kidney drug trial halted early – what happened?
Disease control TerminatedThis early-stage trial tested an experimental drug called AZD3427 in 10 people with heart failure and reduced kidney function. The goal was to see if the drug could improve blood flow to the kidneys, measured with a special PET scan. However, the study was terminated early, so we…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New Heart-Kidney combo drug tested in tiny study
Disease control TerminatedThis early study tested a new drug called AZD5462 added to the standard medicine dapagliflozin in people with heart failure and moderate kidney disease. Only 8 participants were enrolled before the study was stopped. The goal was to see if the combination is safe and affects how …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Bladder cancer drug combo trial halted early – what does it mean?
Disease control TerminatedThis phase 3 trial tested whether adding nivolumab (an immunotherapy drug) to standard BCG treatment could help people with high-risk bladder cancer that came back after BCG alone. Only 13 people enrolled before the study was stopped early, so we don't have clear results on wheth…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 18:24 UTC
-
Kidney drug trial halted: venglustat fails to slow disease
Disease control TerminatedThis study looked at whether taking venglustat earlier versus later could help people with a fast-progressing form of polycystic kidney disease. The trial was stopped early because the main study found the drug did not work well enough. Only 24 people took part, so no clear concl…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 18:08 UTC
-
Pfizer's new cancer combo shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC
-
Kidney transplant hope: drug may remove antibody barriers
Disease control TerminatedThis early study tested a drug called isatuximab in 23 people waiting for a kidney transplant. The goal was to see if it could safely lower immune antibodies that make it hard to find a matching donor. The trial was stopped early, so we have limited information on how well it wor…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 17:59 UTC
-
Cancer combo trial halted early: what went wrong?
Disease control TerminatedThis early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the …
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 17:56 UTC
-
Experimental kidney drug for alport syndrome falls short in early trial
Disease control TerminatedThis phase 2 trial tested a weekly injection of lademirsen in 43 adults with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug could slow the decline in kidney function. The study was terminated early, so the results are limited and it's u…
Phase: PHASE2 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 26, 2026 16:08 UTC
-
Bladder cancer trial halted: could trilaciclib have saved bone marrow?
Disease control TerminatedThis phase 2 trial tested whether adding trilaciclib (Cosela) to standard chemotherapy and avelumab could help people with advanced bladder cancer by protecting their bone marrow. The study enrolled 92 adults with untreated, locally advanced or metastatic urothelial carcinoma. Un…
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC
-
Insulin showdown: toujeo vs tresiba for diabetics with kidney disease
Disease control TerminatedThis study compared two long-acting insulins, Toujeo and Tresiba, in people with type 2 diabetes who also have kidney problems and had never used insulin before. The goal was to see which one controls blood sugar better and causes fewer low blood sugar events. The trial was stopp…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 14:43 UTC
-
New hope for Tough-to-Treat hypertension in kidney patients?
Disease control TerminatedThis study tested a drug called KBP-5074 in 652 adults with moderate-to-severe chronic kidney disease and high blood pressure that was not controlled by at least two other medications. Participants received either KBP-5074 or a placebo daily for up to 52 weeks to see if the drug …
Phase: PHASE3 • Sponsor: KBP Biosciences • Aim: Disease control
Last updated Jun 26, 2026 12:43 UTC
-
New ultrasound technique aims to catch kidney transplant trouble sooner
Diagnosis TerminatedThis study tested a special ultrasound that uses a contrast dye to get clearer images of a new kidney after transplant. The goal was to see if this method could help doctors find early signs of problems like rejection or slow function. The study was small (20 people) and was stop…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
New urine test aims to catch bladder cancer early
Diagnosis TerminatedThis study tested a urine test that measures a protein called DEK to help diagnose bladder cancer. It included over 1,100 people with blood in their urine or painful urination. The goal was to see if the test could accurately detect cancer without invasive procedures. However, th…
Sponsor: Medical Diagnostic Laboratories, LLC • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
Tiny trial on preventive bladder sling halted early — no clear answers
Prevention TerminatedThis study looked at women with pelvic organ prolapse who also had hidden (occult) stress urinary incontinence — leakage that doesn't show up on standard tests. The goal was to see if placing a TOT sling during prolapse surgery could prevent incontinence from appearing later. The…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
Kidney shield? diabetes drug tested to prevent ICU kidney failure
Prevention TerminatedThis study tested whether dapagliflozin, a drug used for diabetes and chronic kidney disease, could prevent acute kidney injury in critically ill patients in the intensive care unit (ICU). The trial planned to enroll 3,000 adults but was terminated early after only 51 participant…
Phase: PHASE3 • Sponsor: The George Institute • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
Kidney shield? experimental drug aims to prevent Post-Surgery kidney damage
Prevention TerminatedThis phase 2 trial tested a drug called GDC-8264 to see if it could prevent acute kidney injury and major kidney problems in people having heart surgery. The study enrolled 67 participants at moderate to high risk. However, the trial was terminated early, so the full results are …
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
Heart surgery kidney shield: roxadustat tested in 98 patients
Prevention TerminatedThis study tested whether taking roxadustat before heart bypass surgery could prevent sudden kidney damage, a common complication. The trial enrolled 98 adults aged 18-80 with planned bypass surgery. The drug aims to help tissues handle low oxygen better. However, the study was t…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
New pain block aims to cut opioid use after kidney surgery
Symptom relief TerminatedThis study looked at whether adding an ultrasound-guided ESP nerve block to standard pain medicine could reduce opioid use and improve pain control after laparoscopic kidney removal for cancer. Ten adults having keyhole kidney surgery were enrolled. The study was stopped early, s…
Phase: NA • Sponsor: McMaster University • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Can an antioxidant supplement ease bladder troubles in older women?
Symptom relief TerminatedThis pilot study tested whether MitoQ, an antioxidant supplement, could improve bladder symptoms like urgency and frequency in women aged 50 and older with metabolic syndrome. Twenty participants took either MitoQ or a placebo for 4 months, tracking their symptoms through questio…
Phase: PHASE2 • Sponsor: Iman Al-Naggar, PhD • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New bundled care approach aims to ease chronic pelvic pain
Symptom relief TerminatedThis study looked at whether a combined treatment plan—including physical therapy, behavioral health therapy, and medical procedures—could reduce symptoms of chronic bladder pain. Researchers compared this bundled approach to usual care in 26 women with interstitial cystitis or b…
Phase: PHASE3 • Sponsor: Jocelyn Fitzgerald • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
New vaginal device aims to stop leaks, but study stalls
Symptom relief TerminatedThis study tested a reusable vaginal pessary device to help women with stress urinary incontinence (leaking urine when coughing, sneezing, or exercising). Each woman acted as her own control, comparing leak amounts with and without the device. The study was terminated early and o…
Phase: NA • Sponsor: Liv Labs Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Pharmacists step in to treat bladder infections in women
Symptom relief TerminatedThis study looked at whether a special protocol used by community pharmacists in France can help women with simple bladder infections (cystitis) get relief more quickly. The goal was to reduce symptoms and avoid unnecessary trips to the doctor or emergency room. The study include…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Can retelling and deep breathing ease trauma in terminal cancer?
Symptom relief TerminatedThis Phase 2 trial tested a neuroscience-based technique combining memory structuring and deep vagal breathing to reduce PTSD symptoms in people with advanced, incurable cancer and their partners. The study enrolled 19 patients who had just received a terminal diagnosis. The appr…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New bladder pain cocktail tested – but study halted early
Symptom relief TerminatedThis study tested a single dose of URG101, a combination of lidocaine and heparin, to see if it safely reduces bladder pain in people with Interstitial Cystitis/Bladder Pain Syndrome. The trial was randomized and double-blind, meaning neither patients nor doctors knew who got the…
Phase: PHASE2 • Sponsor: Urigen • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
New magnetic catheter aims to give control back to men with urinary retention
Symptom relief TerminatedThis study tested a new type of catheter for men who need long-term catheters due to urinary retention. The CymActive catheter has a magnetic valve that lets users control when they urinate, unlike standard catheters that drain continuously. The study aimed to see if it was more …
Phase: NA • Sponsor: Ingenion Medical Limited • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Shocking the bladder: TENS vs PTNS for urgency
Symptom relief TerminatedThis study compared two nerve stimulation treatments—TENS (a skin patch) and PTNS (a needle near the ankle)—for women with overactive bladder who had not gotten relief from lifestyle changes or medication. The goal was to see if TENS works as well as PTNS to improve quality of li…
Phase: NA • Sponsor: University of New Mexico • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Why kidney disease drains your strength: scientists probe muscle fatigue
Knowledge-focused TerminatedThis study investigates why people with advanced chronic kidney disease (stages 3b to 5) often feel tired and weak. Researchers measure handgrip strength and muscle electrical signals in patients aged 60 and older, comparing them to healthy individuals of the same age and sex. Th…
Phase: NA • Sponsor: Centre Hospitalier le Mans • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Which IV fluid is safer for heat stroke? study investigates
Knowledge-focused TerminatedThis study looked at whether using Ringer's lactate instead of normal saline during emergency treatment for heat stroke could reduce the risk of acute kidney injury. Researchers planned to enroll 104 adults diagnosed with heat stroke, giving one group standard saline and the othe…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
ER study aims to perfect antibiotic dosing for urinary infections
Knowledge-focused TerminatedThis study aimed to find the best dose of the antibiotic ceftriaxone for adults with urinary tract infections in the emergency department. Researchers measured how the drug behaves in the body to ensure it stays at effective levels long enough to kill bacteria. The study was stop…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Heart surgery oxygen study halted after just 6 patients
Knowledge-focused TerminatedThis study aimed to understand how oxygen delivery changes during heart surgery when a heart-lung machine is used. Researchers wanted to create a computer model to help doctors personalize oxygen levels for each patient, potentially reducing complications like kidney injury. Only…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Why are people with this rare bone disorder prone to diabetes?
Knowledge-focused TerminatedThis pilot study aims to understand why people with pseudohypoparathyroidism type 1A (PHP1A) have a higher risk of type 2 diabetes. Researchers will measure insulin sensitivity and beta-cell function in 14 participants with PHP1A or related conditions, comparing them to matched h…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Eye test may forecast kidney failure after cancer surgery
Knowledge-focused TerminatedThis study looked at whether special eye scans (OCT-angiography) can predict how well the remaining kidney will work one year after kidney removal for cancer. Researchers enrolled 30 adults scheduled for total nephrectomy. The goal was to see if retinal blood vessel patterns coul…
Phase: NA • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Virtual reality could help measure and treat cancer pain, study suggests
Knowledge-focused TerminatedThis study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Kidney cancer drug study halted after just 6 patients
Knowledge-focused TerminatedThis study aimed to see if the amount of sunitinib in the blood affects side effects and how well the drug works in people with metastatic kidney cancer. Researchers planned to collect extra blood samples during routine visits from patients starting sunitinib as their first treat…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Study aims to predict diabetes risk from common transplant drug
Knowledge-focused TerminatedThis study looked at how the drug tacrolimus, often used after kidney transplants, affects blood sugar and insulin in people with kidney failure who are waiting for a transplant. Researchers wanted to find early signs of diabetes risk so doctors could adjust treatment. The study …
Phase: PHASE4 • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Blood pressure experiment in sepsis halted early – kidney protection still unclear
Knowledge-focused TerminatedThis study tested whether raising the blood pressure target from 65 mmHg to 85 mmHg in patients with septic shock could help prevent kidney injury. Researchers used a drug called norepinephrine to adjust blood pressure and monitored kidney function. The trial was stopped early an…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Dye-Free lung scan may shield kidneys, study hopes
Knowledge-focused TerminatedThis study looked at whether using a VQ scan (which doesn't use kidney-harming dye) instead of a CT scan can prevent acute kidney injury in emergency patients being checked for lung clots. About 253 adults at risk for kidney problems were enrolled. The trial was terminated early,…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Radiation therapy study seeks immune clues in blood
Knowledge-focused TerminatedThis study followed 28 adults with liver, colorectal, melanoma, or kidney cancers who received high-dose radiation therapy. Researchers collected blood samples before, during, and after treatment to track immune cells and other markers. The goal was to learn how the immune system…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Scientists hunt for early warning signs of kidney failure
Knowledge-focused TerminatedThis study aimed to find substances in blood and urine that could signal kidney damage earlier than current tests. Researchers compared samples from healthy volunteers, people with low fluid levels, those at high risk for kidney failure, and patients with acute kidney failure. Th…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Dialysis showdown: which type helps kidney patients live longer?
Knowledge-focused TerminatedThis study compared survival in people with end-stage kidney disease who were randomly assigned to either peritoneal dialysis or hemodialysis. The goal was to see which type of dialysis leads to longer life and fewer complications. The study was conducted in China and was termina…
Phase: NA • Sponsor: Vantive Health LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Bladder cancer drug adstiladrin studied in everyday practice
Knowledge-focused TerminatedThis study followed 202 bladder cancer patients who were prescribed Adstiladrin (nadofaragene firadenovec) in real-world clinics in the US and Israel. Researchers wanted to see how often the drug led to complete remission and how long that lasted. The study was terminated early, …
Sponsor: Ferring Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Can a smartphone app prevent kidney stones from coming back?
Knowledge-focused TerminatedThis study looked at whether using a mobile health platform, alone or with regular doctor visits, helps kidney stone patients follow treatment guidelines and improve their quality of life. Researchers planned to enroll 75 adults who have had kidney stones. The study was terminate…
Phase: NA • Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Kidney education study in arkansas pharmacies halted after just one participant
Knowledge-focused TerminatedThis study aimed to see if teaching chronic kidney disease patients about their condition in a pharmacy could help them choose a dialysis type or consider a transplant. It was designed for adults in Arkansas who were not yet on dialysis. The study was stopped early after only one…
Phase: NA • Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New MRI technique could spot kidney cancer response in just two weeks
Knowledge-focused TerminatedThis study looked at whether a special type of MRI, called Arterial Spin Labeling, can measure blood flow changes in kidney cancer tumors as early as two weeks after starting treatment. The goal was to see if this could help doctors know sooner whether a treatment is working. The…
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
EPO blood pressure mystery: small study halted early
Knowledge-focused TerminatedThis study looked at why erythropoietin (EPO), a drug used to treat anemia, can raise blood pressure in people with chronic kidney disease. Researchers planned to enroll 160 participants but stopped early with only 27. The goal was to measure changes in blood pressure and blood v…
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Blood test may help some ANCA patients skip unnecessary drugs
Knowledge-focused TerminatedThis study looked at whether a specific type of immune cell (CD5+ regulatory B cells) can predict relapse risk in people with ANCA vasculitis, a rare autoimmune disease that damages blood vessels. Researchers aimed to see if patients with normal levels of these cells after initia…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Can a simple urine test replace tumor biopsies for bladder cancer treatment?
Knowledge-focused TerminatedThis study looked at whether genetic changes found in urine could match those in tumor tissue for people with high-risk non-muscle invasive bladder cancer. The goal was to see if a urine test could help doctors choose the best immunotherapy for each patient. The study planned to …
Sponsor: Hopital Foch • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New home care model for kidney disease tested – no dialysis needed
Knowledge-focused TerminatedThis pilot study tested a home-based conservative care program for veterans with advanced chronic kidney disease who chose not to start dialysis. The program involved a team of doctors, nurses, and other specialists providing care at home. Only 2 participants were enrolled before…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Kidney cancer drug safety checked in patients with poor kidney function
Knowledge-focused TerminatedThis study looked at the safety of the cancer drug nivolumab in people with metastatic kidney cancer who also have kidney failure. Researchers planned to compare side effects in 81 patients with different levels of kidney function. However, the study was terminated early, so the …
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:49 UTC
-
Tiny trial tests best way to create dialysis access
Knowledge-focused TerminatedThis pilot study aimed to compare two standard surgical methods for creating an arteriovenous (AV) fistula in the arm for dialysis patients with kidney failure. The goal was to see if a single procedure or two separate procedures leads to better outcomes and quality of life. Howe…
Phase: NA • Sponsor: Tze-Woei Tan • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:22 UTC